Clinical trial
The Feasibility and Safety of Instruments in Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer
NCT02943694 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Feasibility and Safety of Instruments in Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 31, 2016
- Completion date
- December 31, 2018
- Enrollment
- 32 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.